levofloxacin has been researched along with triclosan in 2 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (triclosan) | Trials (triclosan) | Recent Studies (post-2010) (triclosan) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 3,373 | 379 | 1,772 |
| Protein | Taxonomy | levofloxacin (IC50) | triclosan (IC50) |
|---|---|---|---|
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 0.585 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Escherichia coli K-12 | 0.4995 | |
| Carbonyl reductase [NADPH] 1 | Homo sapiens (human) | 0.4 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Haemophilus influenzae Rd KW20 | 0.19 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Bacillus subtilis subsp. subtilis str. 168 | 0.5 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 2.8712 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Francisella tularensis subsp. tularensis SCHU S4 | 1.9125 | |
| Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI | Staphylococcus aureus subsp. aureus MRSA252 | 0.4976 | |
| Enoyl-acyl carrier reductase | Toxoplasma gondii | 0.0167 | |
| Enoyl-acyl-carrier protein reductase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0872 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bonvin, Y; Briet, S; Denis, A; Desroy, N; Drocourt, E; Durant, L; Escaich, S; Faivre, F; Floquet, S; Genevard, JM; Gerusz, V; LeFralliec, G; Moreau, F; Oliveira, C; Oxoby, M; Peltier, L; Prouvensier, L; Raymond, C; Saccomani, M; Sam-Sambo, V; Soulama-Mouze, C; Vongsouthi, V; Walton, A | 1 |
2 other study(ies) available for levofloxacin and triclosan
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
Topics: Animals; Anti-Infective Agents, Local; Benzamides; Cells, Cultured; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Phenyl Ethers; Rats; Structure-Activity Relationship; Triclosan | 2012 |